



UNIVERSITY OF TECHNOLOGY SYDNEY

# **THE EFFECTS AND MECHANISMS OF PAEONIFLORIN ON MURINE OVARIAN CELLS FOR THE TREATMENT OF POLYCYSTIC OVARIAN SYNDROME**

Master of Science (Research) 2018

Name: Madeleine Ong

Supervisor: A/Prof Xianqin Qu

## **Certificate of Original Authorship**

I certify that the work in this thesis has not previously been submitted for a degree nor has it been submitted as part of requirements for a degree except as part of the collaborative doctoral degree and/or fully acknowledged within the text.

I also certify that the thesis has been written by me. Any help that I have received in my research work and the preparation of the thesis itself has been acknowledged. In addition, I certify that all information sources and literature used are indicated in the thesis. This research is supported by an Australian Government Research Training Program Scholarship.

**Signature of Student:**

Production Note:

Signature removed prior to publication.

**Date:**

16/01/2018

## Abstract

Polycystic Ovarian Syndrome (PCOS) is a complex disorder associated with various reproductive, metabolic and cardiovascular abnormalities and is present in approximately 15% of women of reproductive age. The hallmarks include androgen excess, ovulatory dysfunction and insulin resistance which is believed to play a role in the pathogenesis of the disorder. Although the exact mechanisms of PCOS are unknown, intrinsic dysfunction of ovarian theca and granulosa cells are also thought to contribute to altered steroid production and follicle development which may explain the clinical features of the syndrome.

Metformin, an insulin sensitising agent may improve both metabolic and reproductive aspects of the disorder, however, the development of new therapeutic agents for PCOS is still required. Women with PCOS are inclined to seek complementary and alternative treatment options such as Chinese Herbal Medicine, warranting further investigation into the efficacy of the herbs commonly used.

Paeoniflorin, the major compound of the herb, *Radix Paeoniae Albus* has demonstrated the ability to ameliorate insulin resistance in animal models, however the effects and mechanisms of paeoniflorin for the treatment of PCOS has yet to be elucidated.

This study therefore used a dexamethasone-induced *in vitro* model of PCOS in murine theca and granulosa cells to determine the effects of paeoniflorin on secretion of key hormones testosterone, progesterone and oestradiol, cell

proliferation as well as the molecular mechanisms in which paeoniflorin may regulate steroid production. Dexamethasone (10  $\mu$ M) increased theca cell androgen production and adversely affected oestradiol: progesterone ratios in granulosa cells. Meanwhile, paeoniflorin (100  $\mu$ g/mL) decreased androgen production in dexamethasone-induced theca cells and maintained normal oestradiol: progesterone ratios in granulosa cells. In theca cells, this was shown to be through downregulation of cholesterol side-chain cleavage enzyme and 17,20-lyase protein expression. Paeoniflorin also increased mRNA gene expression of *CYP11A1* which may indicate influence over transcription factors or post-translation modifiers, particularly in relation to cell differentiation.

Together, these results suggest that firstly, dexamethasone can be considered a useful *in vitro* model of PCOS in murine ovarian cells. Secondly, paeoniflorin may be a novel agent for the treatment of PCOS by ameliorating hyperandrogenism and improving ovarian function. Further research into the effect of paeoniflorin in differentiation of theca cells as well as the molecular mechanisms in which paeoniflorin attenuates hormones in granulosa cells is needed. Finally, this research can potentially support future animal or clinical studies to further improve the treatment options and quality of life for women with PCOS.

## **Acknowledgements**

I would like to acknowledge and express gratitude to my supervisor, Xianqin Qu and co-supervisor Xingliang Jin for their ongoing support and guidance throughout my study.

A big thank you also to Weiguo Lao for all your help and patience, especially in the laboratory. I would also like to acknowledge fellow students, Kate and Susanna for their encouragement and support as well as the post-graduate cohort on level 7.

Many thanks to Mike, Yi, Eileen, Nahal, Dario, Binhai, Joyce, Nilesh and Jerran for technical advice or assistance given to me and to the laboratory managers, Sarah, Mercedes and Luke for helping me with any questions.

Thank you also to my family and friends for their ongoing love and support and finally and most importantly, my partner Brendan, I couldn't have done this without you.

## **Publications and Communications**

### **Publications**

Ong, M., J. Peng, X. Jin and X. Qu (2017). "Chinese Herbal Medicine for the Optimal Management of Polycystic Ovary Syndrome" *The American Journal of Chinese Medicine* 45(03): 405-422.

Qu, X. and M. Ong (2015). "Successful Treatment of Polycystic Ovarian Syndrome, Nonalcoholic Fatty Liver Disease and Infertility with Chinese Herbal Medicine: A Case Report." *Endocrinology & Metabolic Syndrome* 2015.

Lao, W., X. Jin, Y. Tan, L. Xiao, M. Padula, D. Bishop, B. Reedy, M. Ong, M. Kamal and X. Qu (2016). "Characterisation of Bone Beneficial Components from Australian Wallaby Bone." *Medicines* 3(3): 23.

Kim, M.-S., M. Ong and X. Qu (2016). "Optimal management for alcoholic liver disease: Conventional medications, natural therapy or combination?" *World Journal of Gastroenterology* 22(1): 8-23.

Tan, Y., J. Kim, J. Cheng, M. Ong, W.-G. Lao, X.-L. Jin, Y.-G. Lin, L. Xiao, X.-Q. Zhu and X.-Q. Qu (2017). "Green tea polyphenols ameliorate non-alcoholic fatty liver disease through upregulating AMPK activation in high fat fed Zucker fatty rats." *World Journal of Gastroenterology* 23(21): 3805-3814.

Teng, B., J. Peng, M. Ong and X. Qu (2017). "Successful Pregnancy after Treatment with Chinese Herbal Medicine in a 43-Year-Old Woman with Diminished Ovarian Reserve and Multiple Uterus Fibrosis: A Case Report." *Medicines* 4(1): 7.

### **Communications**

Ong, M., W.Lao, X. Jin and X. Qu (2016). "Paeoniflorin decreases testosterone production in murine ovarian theca cells through down regulation of CYP11A1 and CYP17A1". New Horizons 33rd Combined Health Science Conference, Sydney, Australia

Ong, M., W.Lao, X. Jin and X. Qu (2017). "Paeoniflorin decreases testosterone production in murine ovarian theca cells through down regulation of CYP11A1 and CYP17A1". Annual Scientific Meeting of the Australian Diabetes Society (ADS) and the Australian Diabetes Educators Association (ADEA), Perth, Australia

W.Lao, M. Ong, X. Jin, J. Santos and X. Qu (2017). "Potential therapeutic effects of green tea polyphenols on obesity associated osteoporosis". Annual Scientific Meeting of the Australian Diabetes Society (ADS) and the Australian Diabetes Educators Association (ADEA), Perth, Australia

## List of Figures and Tables

### Figures

#### Chapter 1

1.1 Diagnostic Criteria of PCOS according to the Rotterdam Criteria.....	2
1.2 Folliculogenesis, ovulation and luteinisation of the ovarian follicle.....	13
1.3 Ovarian steroidogenesis in theca and granulosa cells.....	15
1.4 Antral follicle development towards ovulation.....	18
1.5 The role of insulin resistance and hyperinsulinemia in the pathogenesis of PCOS.....	21

#### Chapter 2

2.1 PCOS induction test in theca-granulosa co-culture.....	39
2.2 SYBR green proliferation assay of PFE-treated theca-granulosa co-culture.....	40
2.3 Herbal screening test of herbal compounds on testosterone levels.....	40
2.4 Testosterone and progesterone analysis of paeoniflorin (PFE) treated theca cells.....	41
2.5 Oestradiol, progesterone and their ratios in paeoniflorin (PFE) treated granulosa cells.....	42

#### Chapter 3

3.1 Western blot analysis of CYP17 and CYP11 protein expression in theca cells.....	55
3.2 Immunofluorescence staining of CYP17 and CYP11.....	56
3.3 Quantitative reverse transcriptase polymerase chain reaction analysis of <i>CYP17</i> and <i>CYP11</i> mRNA expression.....	57

### Tables

3.1 Primer sequences of <i>CYP11</i> , <i>CYP17</i> and <i>β-actin</i> .....	53
--	----

## Abbreviations

AMH	Anti-mullerian hormone
AR	Androgen receptor
BPA	Bisphenol A
BSA	Bovine serum albumin
CC	Clomiphene citrate
CHM	Chinese herbal medicine
CM	Complete medium
COC	Combined oral contraceptive pill
CRP	C-reactive protein
CVD	Cardiovascular disease
CYP11	Cytochrome p450 <sub>scc</sub>
CYP17	Cytochrome P450 <sub>17</sub>
DEX	Dexamethasone
DHEA	Dehydroepiandrosterone
DHT	Dihydrotestosterone
DNA	Deoxyribonucleic acid
E2	Oestradiol
ECL	Enhanced chemiluminescent
ER	Endoplasmic reticulum
FBS	Fetal bovine serum
FSH	Follicle stimulating hormone
G	Gravity
GDF-9	Growth differential factor 9
GLUT4	Glucose transporter 4
GnRH	Gonadotropin-releasing hormone
HPLC	High performance liquid chromatography
IL-6	Interleukin 6
IR	Insulin resistance
IRS-1	Insulin receptor substrate 1



IVF	In vitro fertilisation
LH	Luteinising hormone
LHR	Luteinising hormone receptor
MAPK	Mitogen-activated protein kinases
NAFLD	Non-alcoholic fatty liver disease
OCP	Oral contraceptive pill
P	Progesterone
PCOM	Polycystic ovarian morphology
PCOS	Polycystic ovarian syndrome
PCR	Polymerase chain reaction
PFE	Paeoniflorin extract
PI3K	Phosphoinositide 3 kinase
PR	Progeterone receptor
qRT-PCR	Quantitative reverse-transcriptase polymerase chain reaction
RIPA	Radioimmunoprecipitation assay buffer
RNA	Ribonucleic acid
RT	Reverse transcriptase
SHBG	Sex hormone binding globulin
T	Testosterone
T2DM	Type 2 diabetes mellitus
TNF $\alpha$	Tumour necrosis factor alpha

# Contents

<b>PREFIX.....</b>	<b>I</b>
Declaration.....	I
Abstract.....	II
Acknowledgements.....	IV
Publications and Communications.....	V
List of Figures.....	VI
Abbreviations.....	VII
<b>CHAPTER 1: Introduction.....</b>	<b>1</b>
1.1 Polycystic Ovarian Syndrome.....	2
1.1.1 Definition, Diagnosis and Clinical Features.....	2
1.1.2 Epidemiology and Aetiology.....	6
1.1.3 Pathogenesis.....	11
1.1.4 Complications of PCOS.....	22
1.1.5 Conventional Treatment.....	23
1.1.6 Chinese Herbal Medicine.....	25
1.1.7 <i>In vitro</i> models of PCOS.....	28
1.2 Aims of Study.....	30
<b>CHAPTER 2: The Effects of Paeoniflorin Extract on Proliferation and Secretion of Reproductive Hormones in Ovarian Cells.....</b>	<b>32</b>
2.1 Introduction.....	33
2.2 Materials and Methods.....	34
2.2.1 Materials.....	34
2.2.2 Cell Culture.....	35
2.2.3 <i>In Vitro</i> PCOS Induction Test.....	36
2.2.4 Herbal Screening Test.....	36
2.2.5 Paeoniflorin Treatment.....	36
2.2.6 Proliferation Assay.....	37
2.2.7 Testosterone, Oestradiol and Progesterone Measurement.....	37
2.2.8 Statistical Analysis.....	38
2.3 Results.....	38

2.3.1	The Effects of Dexamethasone on Testosterone, Oestradiol And Progesterone Secretion.....	38
2.3.2	The Effects of Paeoniflorin Extract on Ovarian Cell Proliferation.....	39
2.3.3	The Effects of Paeoniflorin On Dexamethasone-Treated Theca And Granulosa Cells.....	40
2.4	Discussion.....	42
<b>CHAPTER 3: The Molecular Mechanisms of Paeoniflorin Extract in Ovarian Theca Cells.....</b>		<b>47</b>
3.1	Introduction.....	48
3.2	Materials and Methods.....	49
3.2.1	Materials.....	49
3.2.2	Western Blotting.....	50
3.2.3	Immunofluorescence Staining.....	51
3.2.4	Quantitative Reverse Transcriptase Polymerase Chain Reaction.....	52
3.2.5	Statistical Analysis.....	52
3.3	Results.....	54
3.3.1	The Effects of Dexamethasone on CYP17 Protein Expression.....	54
3.3.2	The Effects of Paeoniflorin on CYP11 and CYP17 Protein Expression....	55
3.3.3	The Effect of Paeoniflorin on CYP11 Gene Expression.....	57
3.4	Discussion.....	57
<b>CHAPTER 4: Final Discussion, Future Directions and Conclusions.....</b>		<b>57</b>
4.1	Discussion and Future Directions.....	64
4.2	Conclusions.....	67
<b>REFERENCES.....</b>		<b>69</b>